NNVC on NYSE

NANOVIRICIDES, INC.

NANOVIRICIDES, INC. is an American pharmaceutical preparations company based in Shelton.2 Its shares trade on NYSE under the symbol NNVC.2

Price unavailable

Last updated Oct 20, 2026.

Overview

$0Revenue, fiscal 20263
-$8.2MNet income, fiscal 20263

Compare with another stock.

  • TickerNNVC on NYSE2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWest Haven, United States2
  • Incorporated inDE4
  • Business address1 Controls Drive, Shelton, Ct 064844
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI5493003CK9Y2H0OORR732
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O NEVADA AGENCY AND TRANSFER COMPANY, 89501-1977 Reno, United States2
  • Registered withBusiness Center (Secretary of State), E0175172005-82

See how the biggest companies compare on our leaderboards

NanoViricides, Inc. (the “Company”, “NanoViricides”, “we,” or “us”) was incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023. Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at http://www.Nanoviricides.com . We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you should not consider it part of this Annual Report.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-94.7%Return on equity3
-$7.8MFree cash flow3

Financial statements

Revenue6783$0 in 2026
02023: $0$020232024: $0$020242025: $0$020252026: $0$02026
Operating income9106783-$8.3M in 2026−4% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$8.7M-$8.7M20192020: -$8.0M-$8.0M2020−8%2021: -$8.7M-$8.7M2021+9%2022: -$8.1M-$8.1M2022−7%2023: -$8.9M-$8.9M2023+10%2024: -$8.5M-$8.5M2024−5%2025: -$9.6M-$9.6M2025+13%2026: -$8.3M-$8.3M2026−13%
Net income9106783-$8.2M in 2026−2% since 2019
-$15.0M-$10.0M-$5.0M02019: -$8.4M-$8.4M20192020: -$13.4M-$13.4M2020+60%2021: -$8.8M-$8.8M2021−34%2022: -$8.1M-$8.1M2022−8%2023: -$8.6M-$8.6M2023+6%2024: -$8.3M-$8.3M2024−3%2025: -$9.5M-$9.5M2025+14%2026: -$8.2M-$8.2M2026−13%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-06-302025-06-30
Research and development$4.7M$5.5M
General and administrative$3.6M$4.0M
Total operating expenses$8.3M$9.6M
LOSS FROM OPERATIONS-$8.3M-$9.6M
Interest income$87.9K$124.8K
Interest expense-$149
Other income, net$87.9K$124.7K
NET LOSS-$8.2M-$9.5M
Net loss per common share - basic (in dollars per share)-$0.41-$0.63
Net loss per common share - diluted (in dollars per share)-$0.41-$0.63
Weighted average common shares - basic (in shares)20.2M shares15.1M shares
Weighted average common shares - diluted (in shares)20.2M shares15.1M shares

Compare NANOVIRICIDES, INC. with another company

What it owns

What NANOVIRICIDES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$260.0K3 Jun 30, 2026$260.0K3 Jun 30, 20250%
Furniture and fixtures$5.6K3 Jun 30, 2026$5.6K3 Jun 30, 20250%
Leasehold improvements$8.2M3 Jun 30, 2026$8.2M3 Jun 30, 2025+1.0%
Property and equipment, before depreciation$14.7M3 Jun 30, 2026$15.0M3 Jun 30, 2025−2.1%
Accumulated depreciation$8.3M3 Jun 30, 2026$8.2M3 Jun 30, 2025+1.4%
Property and equipment, net$6.4M3 Jun 30, 2026$6.8M3 Jun 30, 2025−6.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.8M3 Jun 30, 2026$1.6M3 Jun 30, 2025+79.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$308.8K3 Jun 30, 2026$317.0K3 Jun 30, 2025−2.6%
Indefinite-lived intangibles (excluding goodwill)$305.6K3 Jun 30, 2026$305.6K3 Jun 30, 20250%
Finite-lived intangibles, gross$153.4K3 Jun 30, 2026$153.4K3 Jun 30, 20250%
Accumulated amortization$150.2K3 Jun 30, 2026$141.9K3 Jun 30, 2025+5.8%
Finite-lived intangibles, net$3.2K3 Jun 30, 2026$11.5K3 Jun 30, 2025−72.1%

Properties, in its own words

Description of Property

The Company’s principal executive offices are located at 1 Controls Drive, Shelton, CT, and include approximately 18,000 square feet of office, laboratory, and cGMP-capable drug manufacturing space. These facilities are fully owned by the Company with no outstanding debt or mortgage.

Item 2 of the 10-K filed Sep 28, 2026.5

Leadership

Who has led NANOVIRICIDES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eugene Seymour2013–2015

President

  1. Anil Diwan2011–2022

Chief financial officer

  1. Meeta Vyas2013–2014
201520202025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorMakarand Jawadekar named Feb 25, 202622
  • DirectorTheodore Edward Rokita named Feb 25, 202622
  • DirectorZucker Edward Brian named Feb 25, 202622

Timeline

  1. Sep 29, 20268-K Executive or director change23
  2. Jul 30, 20268-K Entered a material agreement; Other events24
  3. Jul 17, 20268-K Entered a material agreement25
  4. May 21, 20268-K Regulation FD disclosure26
  5. May 20, 20268-K Entered a material agreement; Other events27
  6. Nov 26, 20258-K Shareholder vote28
  7. Nov 14, 20258-K Entered a material agreement; Unregistered sale of shares; Other events29
  8. Oct 1, 20258-K Executive or director change30
  9. Dec 12, 20248-K Shareholder vote31
  10. Aug 9, 20248-K Executive or director change32
  11. Apr 5, 20248-K Entered a material agreement33
  12. Feb 16, 20248-K Entered a material agreement34
  13. Mar 11, 2013New chief executive Eugene Seymour becomes CEO14

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.10) a share, on Nov 14, 2025.35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

93 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 21 major events, 2 insider forms, 1 private raises, 48 other. The latest 20:

  1. Oct 8, 2026DEF 14A EDGAR
  2. Sep 29, 20268-K EDGAR
  3. Sep 28, 202610-K EDGAR
  4. Sep 3, 2026424B3 EDGAR
  5. Aug 31, 2026EFFECT EDGAR
  6. Aug 21, 2026S-3 EDGAR
  7. Jul 30, 20268-K EDGAR
  8. Jul 27, 2026424B5 EDGAR
  9. Jul 27, 2026424B5 EDGAR
  10. Jul 17, 20268-K EDGAR
  11. Jul 17, 2026424B5 EDGAR
  12. Jul 1, 2026424B3 EDGAR
  13. Jun 26, 2026EFFECT EDGAR
  14. Jun 23, 2026CORRESP EDGAR
  15. Jun 22, 2026DEL AM EDGAR
  16. Jun 18, 2026UPLOAD EDGAR
  17. Jun 17, 2026DEL AM EDGAR
  18. Jun 15, 2026EFFECT EDGAR
  19. Jun 15, 2026S-3 EDGAR
  20. Jun 11, 2026CORRESP EDGAR

The 93 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Anil Diwan PresidentDirector, and CEO$400.0K$440.1K36
2026Meeta VyasChief Finacial Officer67$129.6K$135.4K36
2025Anil Diwan PresidentDirector, and CEO$400.0K$449.8K36
2025Meeta VyasChief Financial Officer67$129.6K$135.9K36

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 12, 2025Raised $6 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 48. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC919,313$1.3M0.0%+407,836
Geode Capital Management, LLC216,022$298.2K0.0%−9,359
Connective Capital Management, LLC185,217$255.6K0.2%New
BlackRock, Inc.158,753$219.1K0.0%+1
Vanguard Fiduciary Trust Co131,923$182.1K0.0%+41,863
Renaissance Technologies LLC128,600$177.5K0.0%−6,300
Miller Financial Services LLC112,000$154.6K0.1%+7,000
UBS Group AG99,331$137.1K0.0%−114,028
Creative Planning86,761$119.7K0.0%New
Susquehanna International Group, Llp60,616$83.7K0.0%−38,415
State Street Corp54,206$74.8K0.0%No change
Northern Trust Corp51,265$70.7K0.0%+27,009
Bridgeway Capital Management, LLC36,039$49.7K0.0%No change
Moss Adams Wealth Advisors LLC21,500$29.7K0.0%No change
Wharton Business Group, LLC15,736$21.7K0.0%No change
Two Sigma Securities, LLC13,816$19.1K0.0%New
Foundations Investment Advisors, LLC10,105$13.9K0.0%+100
TRUE Private Wealth Advisors10,000$13.8K0.0%No change
Sandy Cove Advisors, LLC10,000$13.8K0.0%No change
Osaic Holdings, Inc.9,350$12.9K0.0%+1,700
BankPlus Trust Department7,000$9.7K0.0%No change
EFG International AG4,500$6.2K0.0%No change
Lanark Financial, Inc.4,400$6.1K0.0%+1,000
Vanguard Global Advisers, LLC3,712$5.1K0.0%No change
Tower Research Capital LLC (TRC)3,642$5.0K0.0%−3,274

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 7, 2020Kelly Loeffler, SenateSale$1,001 - $15,000+265.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How NANOVIRICIDES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNANOVIRICIDES, INC.1
  • CIK0001379006
  • Employer ID (EIN)76-06745775
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1 Controls Drive, Shelton, CT 064841
  • Phone(203) 668-55801
  • Shares outstanding25,525,000 shares as of Sep 28, 20265
  • Public float$23.7M as of Dec 31, 20255
  • AuditorEISNERAMPER LLP, Iselin, New Jersey PCAOB ID 274; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceNov 14, 20061
  • Filings555 in all: 4 (124), 8-K (103), 10-Q (55), CORRESP (31), 424B5 (24), UPLOAD (23), NT 10-Q (21), 10-K (19)1
    All 48 form types

    DEF 14A (16), EFFECT (14), NT 10-K (12), S-3 (11), 10-Q/A (9), 10-K/A (8), 424B3 (8), 4/A (6), S-1/A (6), 3 (5), 8-K/A (5), S-3/A (5), SC 13G/A (5), 10QSB (4), D (4), PRE 14A (4), 10SB12G/A (3), DEL AM (3), REGDEX (3), SC 13G (3), S-1 (2), 10KSB (1), 10SB12G (1), 3/A (1), 424B1 (1), 8-A12B (1), CERTNYS (1), DEF 14C (1), DEFA14A (1), DEFR14A (1), DEFR14C (1), FWP (1), NTN 10K (1), POS AM (1), PRE 14C (1), RW (1), S-3MEF (1), S-8 (1), SB-2 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Sep 28, 2026
    Quarterly report (10-Q) May 15, 2026
    Proxy statement (DEF 14A) Oct 8, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
NNVCNYSE

From the cover page of the 10-K filed Sep 28, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks NANOVIRICIDES, INC. names in Item 1A of its 10-K filed Sep 28, 2026: 49 risks under these headings, as written.5

  • Risks Specific to Our Business
  • Our company is a development stage company that has no products approved for commercial sale, never generated any revenues and may never achieve revenues or profitability.
  • Because we are subject to these risks, you may have a difficult time evaluating our business and your investment in our company.
  • Even if we successfully develop and market our drug candidates, we may not generate sufficient or sustainable revenue to achieve or sustain profitability.
  • We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms.
  • We have limited experience in drug development, and may not be able to successfully develop any drugs.
  • Development of pharmaceutical products is a time-consuming process, subject to a number of factors, many of which are outside of our control. Consequently, we can provide no assurance of the successful and timely development of new drugs.
  • We have limited manufacturing expertise and we may have to rely on external manufacturers.
  • We must comply with significant and complex government regulations, compliance with which may delay or prevent the commercialization of our drug candidates.
  • We can provide no assurance that our drug candidates will obtain regulatory approval or that the results of clinical studies will be favorable.
  • Preclinical and clinical studies of our product candidates may not be successful. If we are unable to generate successful results from preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.
  • Because the results of preclinical testing are not necessarily predictive of future results, our products may not have favorable results in our planned clinical trials.
The other 38 risks
  • Even if we obtain regulatory approvals, our marketed drug candidates will be subject to ongoing regulatory review. If we fail to comply with continuing U.S. and foreign regulations, we could lose our approvals to market these drugs and our business would be seriously harmed.
  • Development of our drug candidates requires a significant investment in R&D. Our R&D expenses in turn, are subject to variation based on a number of factors, many of which are outside of our control. A sudden or significant increase in our R&D expenses could materially and adversely impact our results of operations.
  • We will be unable to proceed with our business plan without obtaining additional financing to support our budgeted Clinical Development, Pre-Clinical Research and Development and other costs.
  • The successful development of biopharmaceuticals is highly uncertain. A variety of factors including, pre-clinical study results or regulatory approvals, could cause us to abandon development of our drug candidates.
  • We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials.
  • We are subject to risks inherent in conducting clinical trials. The risk of non-compliance with FDA-approved good clinical practices by clinical investigators, clinical sites, or data management services could delay or prevent us from developing or ever commercializing our drug candidates.
  • Efforts of government and third-party payers to contain or reduce the costs of health care may adversely affect our revenues even if we were to develop an FDA approved drug.
  • We will rely upon licensed patents to protect our technology. We may be unable to obtain or protect such intellectual property rights, and we may be liable for infringing upon the intellectual property rights of others.
  • Other companies or organizations may assert patent rights that prevent us from developing and commercializing our drug candidates.
  • We are dependent upon TheraCour for the rights to develop the products we intend to sell and our license agreements with TheraCour require that TheraCour is the sole developer and supplier of our licensed products.
  • The expiration or loss of patent protection may adversely affect our future revenues and operating earnings.
  • We lack suitable facilities for clinical testing; and rely on third parties.
  • We have limited manufacturing experience.
  • We may be unable to attract, retain, and motivate skilled personnel which will delay our product development programs and our research and development efforts.
  • We have no sales and marketing personnel.
  • Since we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, we cannot predict the timing of any future revenue from these product candidates.
  • We license our core technology from TheraCour and we are dependent upon them as they have exclusive development rights. If we lose the right to utilize any of the proprietary information that is the subject of this license agreement, we may incur substantial delays and costs in development of our drug candidates
  • Our collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return.
  • We employ the use of certain chemical and biological agents and compounds that may be deemed hazardous and we are therefore subject to various environmental laws and regulations. Compliance with these laws and regulations may result in significant costs, which could materially reduce our ability to become profitable.
  • If we use biological and hazardous materials in a manner that causes injury, we may be liable for damages.
  • We depend upon our senior management and their loss or unavailability could put us at a competitive disadvantage.
  • There are conflicts of interest among our officers, directors and stockholders.
  • We anticipate entering into contracts with various U.S. government agencies. In contracting with government agencies, we will be subject to various federal contract requirements. Future sales to U.S. government agencies will depend, in part, on our ability to meet these requirements, certain of which we may not be able to satisfy.
  • We may fail to obtain contracts to supply the U.S. government, and we may be unable to commercialize our drug candidates.
  • If the U.S. government fails to continue funding bio-defense drug candidate development efforts or fails to purchase sufficient quantities of any future bio-defense drug candidate, we may be unable to generate sufficient revenues to continue operations.
  • Risks Related to the Biotechnology/Biopharmaceutical Industry
  • The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises equipped with more substantial resources than us.
  • Risks Related to the Securities Markets and Investments in Our Common Stock
  • General securities market uncertainties resulting from international turmoil.
  • If we do not meet the continued listing standards of the NYSE American our common stock could be delisted from trading, which could limit investors’ ability to make transactions in our common stock and subject us to additional trading restrictions.
  • Our Company is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which will require us to incur audit fees and legal fees in connection with the preparation of such reports. These additional costs will reduce or might eliminate our ability to reach profitability.
  • Our Common Stock may be considered a “penny stock” and may be difficult to sell.
  • Our stock price may be volatile and your investment in our common stock could suffer a decline in value.
  • There is a risk of market fraud.
  • A registration of a significant amount of our outstanding restricted stock may have a negative effect on the trading price of our stock.
  • We do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our capital stock must come from increases in the fair market value and trading price of the capital stock.
  • We may issue additional equity shares to fund the Company’s operational requirements, which would dilute share ownership.
  • Large amounts of our common stock will be eligible for resale under Rule 144.
  • The requirements of complying with the Sarbanes-Oxley act may strain our resources and distract management.
  • Sales of additional equity securities may adversely affect the market price of our common stock and your rights in the Company may be reduced.

Legal proceedings

From time to time, we are a party to legal proceedings arising in the ordinary course of business. We are not currently a party to any legal proceedings that we believe could have a material adverse effect on financial condition or results of operations.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36